glp-1 news today obesity drug updates The Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs FDA UPDATE: A new oral

This plateau indicates that the body has reached a new balance, not that the medication has stopped working

These medications primarily function by enhancing insulin secretion

Data from clinical trials show A1C reductions of 12% when combining these agents, though individual responses vary based on baseline insulin secretion capacity, beta-cell function, and genetic factors influencing GLP-1R expression

Most gastroparesis patients fit the ROME IV criteria for functional dyspepsia

Now, let's get to the news: Blue Cross Blue Shield of Massachusetts , the state's largest commercial health insurer, is rolling back its coverage of GLP-1 drugs like Ozempic and Wegovy for weight loss

It is important to distinguish these symptoms from typical medication-related gastrointestinal symptoms